Lower Serum Level of Anti-tetanus Toxin Antibodies in Patients with Type 2 Diabetes Mellitus

Authors

  • M. Nemati Department of Microbiology and Immunology, Medical School, Kerman University of Medical Sciences, Kerman, Iran.
  • M. Zarrin Department of Microbiology and Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  • S.A. Mir-Abdollahi Department of Microbiology and Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  • M.T. Rezayati Department of Microbiology and Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  • V. Mirzaee Department of Internal Medicine, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  • A. Bagheri Department of Microbiology and Immunology, Medical School, Rafsanjan University of Medical Sciences, Rafsanjan, Iran
  • M. Ebrahimi Pharmacology School, Shiraz University of Medical Sciences, Shiraz, Iran
  • A. Jafarzadeh Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran

Abstract

Aim: to evaluate the serum levels of anti-tetanus toxin antibodies (anti-TTA) in patients with type 2 diabetes mellitus (DM) and in a control group. Methods: totally, 100 patients with type 2 DM and 100 age-and sex-matched healthy individuals were enrolled to study. The presence of type 2 DM confirmed according to the clinical and para-clinical criteria such as fasting plasma glucose above 126 mg/dl. A peripheral blood sample was collected from all subjects. The serum samples of participants tested for the levels of anti-TTA by ELISA method. The serum antitoxin concentration ≥0.1 IU/mL was considered as a protective level of antibody. Results: the seroprotective rate in healthy group was significantly higher than diabetic group (99% vs. 92%; p<0.02). The mean titer of anti-TTA in healthy group (5.32±0.26 IU/ml) was also significantly higher than diabetic patients (3.46±0.26 IU/ml; p<0.001). In diabetic men the mean titer of anti-TTA was significantly higher in comparison to diabetic women (3.94±0.34 IU/ml vs 2.59±0.36 IU/ml; p<0.01). In diabetic patients the seroprotective rate and the mean titer of anti-TTA in subjects with age >40 years was also lower in comparison to those with age <40 years (89.23% vs 97.14%; p<0.15 and 4.57±0.38 IU/ml vs 2.86±0.32 IU/ml; P<0.002, respectively). The mean titer of anti-TTA was significantly higher in patients with diabetes duration <5 years in comparison to patients with disease duration >5 years (3.91±0.35 IU/ml vs 2.85±0.38 IU/ml; p<0.04). Conclusion: these results showed lower levels of anti-TTA in patients with type 2 DM, in diabetic women, in patients aged >40 years and in diabetic patients with disease duration >5 years . Key words: immunity, tetanus, antibody, type 2 diabetes.

Downloads

How to Cite

Nemati, M., Zarrin, M., Mir-Abdollahi, S., Rezayati, M., Mirzaee, V., Bagheri, A., Ebrahimi, M., & Jafarzadeh, A. (2016). Lower Serum Level of Anti-tetanus Toxin Antibodies in Patients with Type 2 Diabetes Mellitus. Acta Medica Indonesiana, 46(1). Retrieved from https://actamedindones.org/index.php/ijim/article/view/63

Issue

Vol. 46 No. 1 (2014)

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.